Related Experiment Video
Updated: Jan 17, 2026

ADSC-sheet Transplantation to Prevent Stricture after Extended Esophageal Endoscopic Submucosal Dissection
Published on: February 10, 2017
Efficacy and safety of endoscopic submucosal dissection for pyloric neoplasms
Shao-Bin Luo1,2, Zu-Qiang Liu1,2, Li Wang1,2,3
1Endoscopy Center and Endoscopy Research Institute, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Background And Aims:
Although endoscopic resection is widely accepted for pyloric lesions, endoscopic submucosal dissection (ESD) of pyloric neoplasms remains technically challenging. The study aimed to assess the efficacy and safety of ESD for pyloric neoplasms.
Methods:
From June 2011 to August 2024, we retrospectively analyzed 103 patients with pyloric neoplasms who underwent ESD at the Endoscopy Center of Zhongshan Hospital. Clinical data, including patient demographics, procedural outcomes, and follow-up results, were collected.
Results:
Among 103 lesions, there were 36 prepyloric neoplasms, 49 pyloric neoplasms and 18 postpyloric neoplasms. The median lesion size was 31 mm (range 10-85 mm). The postpyloric group showed longer procedure duration (32 min vs. 39 min vs. 46 min, P = 0.029) and lower rate of en bloc resection (100.0% vs. 95.9% vs. 83.3%, P = 0.026) compared with the prepyloric group and pyloric group. No patients required conversion to open surgery. After procedure, delayed bleeding occurred in one patient each from the prepyloric and pyloric groups. During a median follow-up of 25 months (range: 6-81 months), only one recurrence (pyloric group) was observed. Post-ESD pyloric stenosis developed in 5 patients, all of whom achieved symptomatic relief through endoscopic balloon dilation (EBD) without complications.
Conclusions:
ESD is a feasible and safe treatment for pyloric neoplasms. Additionally, EBD appears to be a safe and effective therapeutic approach for post-ESD pyloric stenosis.
Related Concept Videos
Peptic Ulcer Disease V: Surgical Management and Nursing Care
Surgical Interventions for Peptic Ulcer Disease
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Endoscopic Procedures I: Esophagogastroduodenoscopy
During an EGD, the endoscope can be used to:
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
